Drug intelligence / Profile preview

epibatidine

Development stage
Preclinical
Modality
Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Administration
Injection (experimental/animal Studies)
01

Overview

Epibatidine is a potent piperidine alkaloid originally isolated from the skin of the Ecuadorian poison frog Epipedobates anthonyi (formerly Epipedobates tricolor). It acts as a highly potent analgesic—at least 200 times more powerful than morphine—but its therapeutic window is extremely narrow due to severe toxicity at doses only slightly above those required for pain relief[4][5][10]. Unlike most traditional analgesics that target opioid receptors, epibatidine is a full agonist at neuronal nicotinic acetylcholine receptors (nAChRs), especially subtypes alpha4/beta2 and alpha3/beta2[4][5]. It also binds to other nAChRs in the brain and neuromuscular junctions throughout the body, which can result in adverse effects such as seizures, hypertension, bradycardia, muscular paresis, and potentially fatal respiratory paralysis[4][5]. The compound has been studied primarily in animal models; its high toxicity has precluded clinical development as an analgesic in humans. Research into safer analogs continues due to its unique mechanism of action.

Other names
(+)-epibatidine(1R,2R,4S)-2-(6-chloro-3-pyridinyl)-7-azabicyclo[2.2.1]heptaneexo-2-(6-chloro-3-pyridinyl)-7-azabicyclo[2.2.1]heptane
02

Targets

α4β2 nAChR (Nicotinic acetylcholine receptor alpha4 beta2 subtype)α3β2 nAChR (α3β2 nicotinic receptor)

Beyond the preview

Go deeper on epibatidine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on epibatidine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call